Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 19/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198584 | 0.98 | HDAC3 (0.44) | HDAC3HDAC1HDAC2NCOR2HDAC4 | |
| SCHEMBL10198753 | 0.98 | HDAC3 (0.44) | HDAC3HDAC1HDAC2NCOR2HDAC4 | |
| SCHEMBL14117660 | 0.97 | HDAC3 (0.43) | HDAC3HDAC1HDAC2NCOR2HDAC4 | |
| SCHEMBL879578 | 0.95 | HDAC3 (0.47) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL85876 | 0.95 | HDAC3 (0.47) | HDAC3HDAC1HDAC2NCOR2HDAC4 | |
| SCHEMBL10198591 | 0.95 | HDAC3 (0.45) | HDAC3HDAC1HDAC2NCOR2HDAC4 | |
| SCHEMBL19945148 | 0.95 | HDAC3 (0.42) | HDAC3HDAC1HDAC2NCOR2HDAC4 | |
| SCHEMBL19940162 | 0.92 | HDAC3 (0.40) | HDAC3HDAC1HDAC2NCOR2HDAC4 | |
| SCHEMBL85723 | 0.88 | PLK4 (0.38) | HDAC8HDAC6 | |
| SCHEMBL18116453 | 0.88 | PLK4 (0.38) | HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093636-A1 | Arylamide compounds and compositions and uses thereof | INNOVATION PHARMACEUTICALS INC. | 2021-04-01 | — | — | US | disclosed |
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190314370-A1 | Arylamide compounds and compositions and uses thereof | POLYMEDIX, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10166232-B2 | Arylamide compounds and compositions and uses thereof | INNOVATION PHARMACEUTICALS INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-7745662-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745662-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | POLYMEDIX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553876-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090092574-A1 | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2009-04-09 | — | — | US | disclosed |
| US-20090092574-A1 | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2009-04-09 | — | — | US | disclosed |
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2008-07-24 | — | — | US | disclosed |
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176807-A1 | Facially amphiphilic polymers and oligomers and uses thereof | TLR3, ABHD16A, ANTXR2 | HDAC3 376/4885HDAC1 1308/4885HDAC2 2540/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC1 562/4885HDAC2 432/4885 |
| US-10166232-B2 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | HDAC3 748/4885HDAC1 1346/4885HDAC2 949/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | HDAC3 291/4885HDAC1 405/4885HDAC2 314/4885 |
| US-20190314370-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | HDAC3 748/4885HDAC1 1346/4885HDAC2 949/4885 |
| US-20090092574-A1 | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof | OTC, OCIAD2, OCIAD1 | HDAC3 2109/4885HDAC1 2886/4885HDAC2 3308/4885 |
| US-20090239811-A1 | POLYCATIONIC COMPOUNDS AND USES THEREOF | VEGFA, VHL, PGF | HDAC3 136/4885HDAC1 156/4885HDAC2 671/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | HDAC3 328/4885HDAC1 562/4885HDAC2 432/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | HDAC3 291/4885HDAC1 405/4885HDAC2 314/4885 |
| US-20210093636-A1 | Arylamide compounds and compositions and uses thereof | AADAC, AAAS, AHR | HDAC3 748/4885HDAC1 1346/4885HDAC2 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.